Drug updated on 3/28/2024
| Dosage Form | Injection (subcutaneous: 3120 mcg/1.56 mL) |
| Drug Class | Human parathyroid hormone related peptide analogs |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- For the treatment of postmenopausal women with osteoporosis at high risk for fracture.
Summary
- Abaloparatide (Tymlos) is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture.
- Four systematic reviews/meta-analyses were reviewed to gather information about this drug's effectiveness and safety in its target population.
- According to one meta-analysis, abaloparatide demonstrated a beneficial effect on bone mineral density compared to both placebo and teriparatide, another treatment option for postmenopausal osteoporosis; it also had insignificantly lowered adverse event risk than teriparatide.
- Another study found that while several drugs reduced both vertebral and nonvertebral fractures in secondary prevention of osteoporotic fractures in postmenopausal women, abaloparatide increased withdrawal risk due to side effects; however, romosozumab, teriparatide, denosumab and risedronate were identified as optimal treatments considering efficacy and safety together.
- A third review concluded that among bone anabolic therapies including abaloparatide (Tymlos), romosozumab was consistently ranked better at increasing bone mineral density across all locations but when it came down to reducing vertebral/non-vertebral fractures or increasing bone formation - Abalapratride stood out as the best choice amongst other treatments like Teriperatride etc.
- Lastly according a network meta-analysis conducted by comparing various studies showed that Tymlos significantly reduces the relative risks of vertebral fracture, non-vertebrae fracture & wrist fracture versus placebo when compared with other available treatment options which makes it highly effective against Osteoperosis.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Tymlos (abaloparatide) Prescribing Information. | 2021 | Radius Health, Inc., Waltham, MA |
Systematic Reviews / Meta-Analyses
Clinical Practice Guidelines
| Document Title | Year | Source |
|---|---|---|
| American Association of Clinical Endocrinologists/American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis—2020 update. | 2020 | Endocrine Practice |
| Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society* clinical practice guideline. | 2019 | The Journal of Clinical Endocrinology & Metabolism |